Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 open-label study of givinostat in Japanese patients with Duchenne muscular dystrophy
jRCT2071260086Phase 2Recruiting
- Sponsor
- JCR Pharmaceuticals
- Start
- Sep 2026
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of givinostat in Duchenne muscular dystrophy (DMD), sponsored by JCR Pharmaceuticals. Primary endpoints: Adverse events and serious adverse events after 6 months, Type, incidence, causality and severity of adverse events and 4 more. Started Sep 2026; status: recruiting.
02
Drugs
givinostat
03
Conditions
Duchenne muscular dystrophy (DMD)
Beyond the preview
Go deeper on jRCT2071260086.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2071260086.